ICM
AVDL

Invenomic Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Invenomic Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-802,994
Closed -$7.11M – 146
2025
Q2 		$7.11M Buy
802,994
+574,968
+252% +$5.05M 0.4% 78
2025
Q1 		$1.79M Buy
+228,026
New +$1.91M 0.09% 155

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Invenomic Capital Management's AVDL Position: Q3 2025 in Review

Invenomic Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 802,994 shares — an estimated $7.11M sold.

Invenomic Capital Management first reported a position in AVDL in Q1 2025 and held it in 2 quarters. The position peaked at $7.11M in Q2 2025. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Invenomic Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 802,994 Avadel Pharmaceuticals shares in Q3 2025, an estimated $7.11M.
  • Invenomic Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Invenomic Capital Management's Avadel Pharmaceuticals position peaked at $7.11M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Invenomic Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.